Benzylguanidines and other galegine analogues inducing weight loss in mice.

Dimethylallylguanidine, also known as galegine, isolated from Galega officinalis, has been shown to have weight reducing properties in vivo. Substitution of the guanidine group with an N-cyano group and replacement of guanidine with amidine, pyrimidine, pyridine, or the imidazole moieties removed the weight reducing properties when evaluated in BALB/c mice. However, retention of the guanidine and replacement of the dimethylallyl group by a series of functionalized benzyl substituents was shown to exhibit, and in some cases significantly improve, the weight reducing properties of these molecules in BALB/c, ob/ob, and diet induced obesity (DIO) mice models. The lead compound identified, across all models, was 1-(4-chlorobenzyl)guanidine hemisulfate, which gave an average daily weight difference (% from time-matched controls; +/- SEM) of -19.7 +/- 1.0, -11.0 +/- 0.7, and -7.3 +/- 0.8 in BALB/c, ob/ob, and DIO models, respectively.

[1]  M. Botta,et al.  Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents. , 2008, Journal of medicinal chemistry.

[2]  B. Furman,et al.  Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice , 2008, British journal of pharmacology.

[3]  A. Karapetyan,et al.  Synthesis and antimonoamineoxidase activity of 4-methoxybenzylguanidine and its sulfate , 1998, Pharmaceutical Chemistry Journal.

[4]  M. Kakei,et al.  Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. , 2005, Endocrine journal.

[5]  E. Hesse,et al.  Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel , 1929, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[6]  C. Day,et al.  Metformin: its botanical background , 2004 .

[7]  J. Rothbard,et al.  Guanidinium rich peptide transporters and drug delivery. , 2003, Current protein & peptide science.

[8]  L. Witters The blooming of the French lilac. , 2001, The Journal of clinical investigation.

[9]  T. Vidmar,et al.  Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid. , 2001, Journal of medicinal chemistry.

[10]  C. Bouchard,et al.  Gene-diet interactions in obesity. , 2000, The American journal of clinical nutrition.

[11]  E. Vesell,et al.  Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. , 2000, Toxicology.

[12]  A. Gray,et al.  Novel Weight‐Reducing Activity of Galega officinalis in Mice , 1999, The Journal of pharmacy and pharmacology.

[13]  C. Boyd,et al.  Transporters for cationic amino acids in animal cells: discovery, structure, and function. , 1998, Physiological reviews.

[14]  M. Villarroya,et al.  Synthesis and pharmacology of alkanediguanidinium compounds that block the neuronal nicotinic acetylcholine receptor. , 1996, Bioorganic & medicinal chemistry.

[15]  J. Luo,et al.  Study of phenformin metabolism in rat liver microsomes by HPLC, CE and on-line HPLC-electrospray ionization mass spectrometry. , 1996, Biomedical chromatography : BMC.

[16]  I. Leito,et al.  Basicity of 3-aminopropionamidine derivatives in water and dimethyl sulphoxide. Implication for a pivotal step in the synthesis of distamycin A analogues , 1996 .

[17]  Dominic P. Williams,et al.  The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  P Watts,et al.  The influence of medium composition on the maintenance of cytochrome P-450, glutathione content and urea synthesis: a comparison of rat and sheep primary hepatocyte cultures. , 1995, Journal of hepatology.

[19]  A. Hinchliffe,et al.  Relationships between the HOMO energies and pKa values in monocyclic and bicyclic azines , 1995 .

[20]  J. Idle,et al.  The genetic control of phenformin 4-hydroxylation. , 1985, Journal of medical genetics.

[21]  E. Bosisio,et al.  Defective Hydroxylation of Phenformin as a Determinant of Drug Toxicity , 1981, Diabetes.

[22]  G. Kolata The phenformin ban: is the drug an imminent hazard? , 1979, Science.

[23]  J. C. Emmett,et al.  CYANOGUANIDINE‐THIOUREA EQUIVALENCE IN THE DEVELOPMENT OF THE HISTAMINE H2‐RECEPTOR ANTAGONIST, CIMETIDINE , 1977 .

[24]  G. Scholtysik,et al.  Substituted phenylacetylguanidines: a new class of antihypertensive agents. , 1975, Arzneimittel-Forschung.

[25]  D. Molho,et al.  [Synthesis and pharmacologic selection of new antihypertensive agents]. , 1968, Therapie.

[26]  M. Roginsky,et al.  PHENFORMIN IN HUMAN OBESITY , 1968, Annals of the New York Academy of Sciences.

[27]  A. Mckay,et al.  Acylation of guanidines and guanylhydrazones , 1967 .

[28]  T. Darby,et al.  Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. , 1967, Journal of medicinal chemistry.

[29]  V. Parrino,et al.  Hypoglycemic Agents. IV.1—3 N1,N5-Alkyl- and Aralkylbiguanides , 1959 .

[30]  V. Parrino,et al.  Hypoglycemic Agents. I.1 Chemical Properties of β-Phenethylbiguanide.2 A New Hypoglycemic Agent3 , 1959 .

[31]  G. Ungar,et al.  Pharmacological Studies of a New Oral Hypoglycemic Drug , 1957, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[32]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[33]  C. E. Braun,et al.  The Preparation of Some Monoguanidines of Possible Physiological Significance1 , 1934 .